Genitourinary Cancers | Specialty

Future Directions in Renal Cell Carcinoma Management

March 29th 2019

Further Exploring TKI/I-O Combination Regimens in mRCC

March 29th 2019

mRCC: When is TKI/I-O Combination Therapy Appropriate?

March 29th 2019

Novel Combinations in mRCC: Axi/Pembro vs Axi/Avelumab

March 29th 2019

Goals in Previously Treated Advanced Renal Cell Carcinoma

March 29th 2019

Selecting an Optimal Second-Line Regimen for mRCC

March 29th 2019

Frontline Therapy for mRCC: Sequencing and Goals

March 29th 2019

Evaluating I-O Monotherapy's Value in Treating mRCC

March 29th 2019

mRCC: Identifying and Managing AEs in TKIs and IO Therapy

March 29th 2019

Role of TKIs in Intermediate or Poor-Risk mRCC

March 29th 2019

Favorable-Risk mRCC: Choosing Appropriate Frontline Therapy

March 29th 2019

Risk Stratification in Metastatic Renal Cell Carcinoma

March 29th 2019

Fox Chase Investigates Screening Methods to Avoid Unnecessary Radical Cystectomy

March 28th 2019

Currently, there is no reliable way to identify who can safely avoid radical cystectomy following MIBC treatment. For this reason, Fox Chase Cancer Center researchers are trying to find the as-yet-elusive 30% by asking 3 important questions.

Enfortumab Vedotin Active After Chemo and Immunotherapy in Urothelial Carcinoma

March 28th 2019

Enfortumab vedotin showed strong clinical activity in patients with locally advanced or metastatic urothelial carcinoma who previously received both platinum-containing chemotherapy and immune checkpoint therapy, according to topline results from the pivotal phase II EV-201 trial.

Dr. Somer on Optimal Combinations in mRCC

March 27th 2019

Bradley G. Somer, MD, an associate professor of hematology/oncology and head of strategic expansion/development at the University of Tennessee West Cancer Center, discusses optimal combinations for the treatment of patients with metastatic renal cell carcinoma (mRCC) in the frontline setting.

Dr. Quinn on Targetable Molecular Pathways in RCC

March 26th 2019

David I. Quinn, MBBS, PhD, associate professor of medicine, section head, Genitourinary Oncology, Division of Cancer Medicine and Blood Diseases, USC Keck School of Medicine, discusses targetable molecular pathways in renal cell carcinoma.

Bladder Cancer Guidelines Showcase Advent of Immunotherapy

March 24th 2019

Thomas W. Flaig, MD, discusses the latest updates to the NCCN guidelines for the treatment of patients with muscle-invasive bladder cancer and highlights the latest approvals of checkpoint inhibitors in this patient population.

Dr. Sznol on Unanswered Questions With Immunotherapy in RCC

March 22nd 2019

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses unanswered questions with immunotherapy in the treatment of patients with renal cell carcinoma.

Frontline Combos Poised to Change NCCN Guidelines in Advanced RCC

March 22nd 2019

The 2019 National Comprehensive Cancer Network guideline on the management of advanced clear cell renal cell carcinoma undergoes a major shift in risk category used to define preferred and alternative first-line treatments.

Exploring the Role of Cytoreductive Nephrectomy in RCC

March 22nd 2019

Brian M. Shuch, MD, highlights the complex data with cytoreductive nephrectomy in renal cell carcinoma and offers advice on how to navigate the intricate treatment landscape.